(259 days)
Not Found
Yes
The device description explicitly states that "Computer vision and machine learning algorithms are applied" and the performance studies section mentions "machine learning algorithms".
No
The device is described as a "computer-aided detection device intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules" and explicitly states it "must not be used as a sole source for treatment decisions." It provides diagnostic information, not therapy.
Yes
The text explicitly states that the device is "intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules" and acts as "part of the diagnostic chain".
No
The device description explicitly states that the system includes hardware components: the "Infinity Box" and the "Infinity Sensor." These are physical devices that connect to the ultrasound system and transducer, respectively, and are necessary for the system's functionality.
Based on the provided information, the PIUR tUS Infinity is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to obtain information for diagnostic or monitoring purposes.
- PIUR tUS Infinity's Function: The PIUR tUS Infinity processes and analyzes ultrasound images acquired from an FDA-cleared ultrasound system. It does not interact with or analyze biological specimens taken from the patient. Its input is image data, not biological samples.
- Intended Use: The intended use clearly states it's a "computer-aided detection device intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules acquired from FDA-cleared ultrasound systems." This focuses on image analysis and reporting, not the analysis of biological samples.
- Device Description: The device description details how it processes ultrasound images and sensor data to generate 3D volumes and perform image analysis. There is no mention of handling or analyzing biological specimens.
Therefore, the PIUR tUS Infinity falls under the category of a medical device that processes and analyzes medical images, rather than an In Vitro Diagnostic device.
No
The letter does not state that the FDA has reviewed and approved or cleared a Predetermined Change Control Plan (PCCP) for this specific device.
Intended Use / Indications for Use
PIUR tUS Infinity is a computer-aided detection device intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules acquired from FDA-cleared ultrasound systems, including image documentation, analysis, and reporting. The device supports the physician with additional information during image review, including quantification and visualization of sonographic characteristics of thyroid nodules.
PIUR tUS Infinity may be used on any adult patient aged 22 and older, independent of gender, linquistic and cultural background, or health status, unless any of the contraindications apply.
The PIUR tUS Infinity acts as part of the diagnostic chain and must not be used as a sole source for treatment decisions, but as an add-on solution to regular 2D ultrasound imaging.
PIUR tUS Infinity device is not intended for body contact (including skin. mucosal membrane, breached or compromised surfaces, blood path indirect, tissues, bones, dentin, or circulation blood),
Product codes
QIH
Device Description
PIUR tUS Infinity is a computer-aided solution to aid in the diagnostic workflow of thyroid and thyroid nodules, including image documentation, analysis, and reporting. Computer vision and machine learning algorithms are applied to a sequence of ultrasound images of the thyroid that have been acquired by a compatible FDA-cleared ultrasound system. The solution identifies the thyroid lobe and proposes its margins to the user who then can make adjustments to the segmentation and approve the final result. Based on this, a lobe volume is calculated. With additional user input, thyroid nodules can be marked, quantified, and visualized as multiplanar reconstructions or 3D volume renderings. The system provides a user interface for the user to select the five ACR TI-RADS parameters and calculates the ACR TI-RADS level from the user input for each nodule. All proposed results must be verified, adjusted if necessary, and confirmed by the user before they can be added to an automatically generated clinical report.
The Infinity software runs on a stand-alone computer (Infinity Workstation - not part of the medical product) that fulfils the defined minimum requirements. It takes as an input a sequence of ultrasound images that are transmitted from the ultrasound to the Infinity Workstation wirelessly through the Infinity Box. The Infinity Box is a piece of hardware that connects to compatible standard ultrasound systems via digital video output such as HDMI or DVI. It grabs 2D ultrasound images through a video grabber and transfers the images to the Infinity Workstation via Wi-Fi in real-time. In addition, a small Infinity Sensor must be clipped onto the ultrasound transducer using individually designed attachments. An inertial measurement unit (IMU) tracks the orientation of the transducer during the scan and sends this information to the Infinity Workstation via Bluetooth. The Infinity Workstation combines information from the Infinity Box and Sensor to generate tomographic 3D ultrasound volumes on which the abovedescribed image analysis can be performed.
The PIUR tUS Infinity acts as part of the diagnostic chain only and must not be used as a sole source for diagnostic or treatment decisions.
The solution is intended to be used on patients aged 22 and older, independent of gender, linguistic and cultural background, or health status, unless any of the contraindications apply, in a non-sterile environment. The solution is not intended to be used on patients with open wounds or irritated skin or during surgery.
Mentions image processing
Yes. "The device performs 2D to 3D reconstruction to generate volumetric data of a thyroid."
Mentions AI, DNN, or ML
Yes. "Computer vision and machine learning algorithms are applied to a sequence of ultrasound images of the thyroid" and "Based on computer vision, machine learning, pattern recognition and quantification method."
Input Imaging Modality
Ultrasound
Anatomical Site
Thyroid and thyroid nodules
Indicated Patient Age Range
adult patient aged 22 and older
Intended User / Care Setting
medical professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
To validate the safety and performance of the PIUR tUS Infinity System software and machine learning algorithms, PIUR conducted performance testing that consisted of two major parts:
-
- Volume Measurement Validation
- a. Demonstrate non-inferiority of volume measurements against conventional protocol using:
- i. Standardized (%) absolute inter-observer differences
- ii. Lin's Concordance Correlation Coefficient
- iii. Mean Squared Error
-
- ACR TI-RADS Classification Validation
- a. Demonstrate non-inferiority of the PIUR tUS Infinity in ACR TI-RADS classification against conventional 2D ultrasound using Weighted Cohen's Kappa coefficient in 196 male and female patients (US, Europe & Brazil) across multiple ethnicities and using 7 ultrasound models (covering low-end, mid-range, and high-end scanners).
- b. In addition, PIUR assessed performance for individual ACR TI-RADS subparameters to exclude bias or distortion introduced by 3D reconstruction using a sub-set of 102 patients. Weighted Cohen's Kappa Coefficients and Limits of Agreement for ultrasound categories (total score, composition, echogenicity, shape, margin and echogenic foci) were assessed on thyroid nodules.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
PIUR Imaging conducted summative usability evaluation, performance validation testing and software verification and validation testing of the PIUR tUS Infinity system. The results of the usability and performance validation testing demonstrated that the PIUR tUS Infinity system provides accurate representation of key processing parameters under a range of clinically relevant parameters associated with the intended use of the software performance, validation and verification testing demonstrated that the PIUR IUS Infinity system met all design requirements and specifications.
To validate the safety and performance of the PIUR tUS Infinity System software and machine learning algorithms, PIUR conducted performance testing that consisted of two major parts:
-
- Volume Measurement Validation
- a. Demonstrate non-inferiority of volume measurements against conventional protocol using:
- i. Standardized (%) absolute inter-observer differences
- ii. Lin's Concordance Correlation Coefficient
- iii. Mean Squared Error
-
- ACR TI-RADS Classification Validation
- a. Demonstrate non-inferiority of the PIUR tUS Infinity in ACR TI-RADS classification against conventional 2D ultrasound using Weighted Cohen's Kappa coefficient in 196 male and female patients (US, Europe & Brazil) across multiple ethnicities and using 7 ultrasound models (covering low-end, mid-range, and high-end scanners).
- b. In addition, PIUR assessed performance for individual ACR TI-RADS subparameters to exclude bias or distortion introduced by 3D reconstruction using a sub-set of 102 patients. Weighted Cohen's Kappa Coefficients and Limits of Agreement for ultrasound categories (total score, composition, echogenicity, shape, margin and echogenic foci) were assessed on thyroid nodules.
Electrical safety and EMC testing were conducted on the PIUR Infinity. The testing complies with the applicable sections of IEC 60601-1:2013, Medical electrical equipment – Part 1: General requirements for basic safety and essential performance. IEC 60601-1-2:2014, Medical electrical equipment – Part 1-2: General requirements for the basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests, and IEC 60601-2-37:2016, Medical electrical equipment - Part 2-37: Particular requirements for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment. An additional white-noise test verified that the use of the wireless PIUR tUS Infinity equipment does not induce any additional white noise band in the ultrasound image, and therefore, does not degrade the quality of ultrasound images.
Together with software verification and validation, safety and performance testing demonstrated that PIUR tUS Infinity system satisfies all design requirements and device specifications and is substantially equivalent to the Predicate Device.
Key Results: "The results of the usability and performance validation testing demonstrated that the PIUR tUS Infinity system provides accurate representation of key processing parameters under a range of clinically relevant parameters associated with the intended use of the software performance, validation and verification testing demonstrated that the PIUR IUS Infinity system met all design requirements and specifications."
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Volume Measurement Validation: Standardized (%) absolute inter-observer differences, Lin's Concordance Correlation Coefficient, Mean Squared Error.
ACR TI-RADS Classification Validation: Weighted Cohen's Kappa coefficient.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
PIUR Imaging GmbH % Jennifer Willner JW Regulatory Consulting LLC 406 Wacouta St, Suite 417, St. Paul MN 55101 USA
Re: K240036
September 20, 2024
Trade/Device Name: PIUR tUS Infinity Regulation Number: 21 CFR 892.2050 Regulation Name: Medical Image Management And Processing System Regulatory Class: Class II Product Code: QIH Dated: August 22, 2024 Received: August 22, 2024
Dear Milos Stojanovic:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory
2
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jessica Lamb
Jessica Lamb, Ph.D. Assistant Director Imaging Software Team DHT 8B: Division of Radiological Imaging Devices and Electronic Products OHT 8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
Submission Number (if known)
Device Name
PIUR tUS Infinity
Indications for Use (Describe)
PIUR tUS Infinity is a computer-aided detection device intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules acquired from FDA-cleared ultrasound systems, including image documentation, analysis, and reporting. The device supports the physician with additional information during image review, including quantification and visualization of sonographic characteristics of thyroid nodules.
PIUR tUS Infinity may be used on any adult patient aged 22 and older, independent of gender, linquistic and cultural background, or health status, unless any of the contraindications apply.
The PIUR tUS Infinity acts as part of the diagnostic chain and must not be used as a sole source for treatment decisions, but as an add-on solution to regular 2D ultrasound imaging.
PIUR tUS Infinity device is not intended for body contact (including skin. mucosal membrane, breached or compromised surfaces, blood path indirect, tissues, bones, dentin, or circulation blood),
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(K) SUMMARY
510(k) Number: K240036
Date Prepared: September 20, 2024
Table 1: Submitter Information
| Manufacturer: | Manufacturer's Contact Person: |
|---|---|
| PIUR Imaging GmbH | Jennifer Willner |
| Hamburgerstr. 11/Top 7 | President JW Regulatory Consulting LLC |
| 1050 Vienna Austria | Phone: +1 (612) 240-8904 |
| US FDA ERN: Pending | Email: Jennifer@JWRegulatoryConsulting.com |
| Trade Name | PIUR tUS Infinity |
|---|---|
| Common Name | PIUR tUS Infinity |
| Classification Name | Picture Archiving and Communications System |
| Regulation | 21 CFR 892.2050 |
| Product Code | QIH |
| Regulatory Classification: | Class II |
| Device Panel: | Radiology (OHT8) |
Table 2: Device Information
The PIUR tUS Infinity is substantially equivalent to the previously cleared predicate AmCAD-UT (Table 3). Neither of these have been subject to a design-related recall.
Table 3: Predicate Devices
| Predicate Device | Manufacturer | FDA 510(k) |
|---|---|---|
| AmCAD-UT | AmCad BioMed Corporation | K203555 |
Device Description
PIUR tUS Infinity is a computer-aided solution to aid in the diagnostic workflow of thyroid and thyroid nodules, including image documentation, analysis, and reporting. Computer vision and machine learning algorithms are applied to a sequence of ultrasound images of the thyroid that have been acquired by a compatible FDA-cleared ultrasound system. The solution identifies the thyroid lobe and proposes its margins to the user who then can make adjustments to the segmentation and approve the final result. Based on this, a lobe volume is calculated. With additional user input, thyroid nodules can be marked, quantified, and visualized as multiplanar reconstructions or 3D volume renderings. The system provides a user interface for the user to select the five ACR TI-RADS parameters and calculates the ACR TI-RADS level from the user input for each nodule. All proposed results must be verified, adjusted if necessary, and confirmed by the user before they can be added to an automatically generated clinical report.
The Infinity software runs on a stand-alone computer (Infinity Workstation - not part of the medical product) that fulfils the defined minimum requirements. It takes as an input a sequence of ultrasound images that are transmitted from the ultrasound to the Infinity Workstation
5
wirelessly through the Infinity Box. The Infinity Box is a piece of hardware that connects to compatible standard ultrasound systems via digital video output such as HDMI or DVI. It grabs 2D ultrasound images through a video grabber and transfers the images to the Infinity Workstation via Wi-Fi in real-time. In addition, a small Infinity Sensor must be clipped onto the ultrasound transducer using individually designed attachments. An inertial measurement unit (IMU) tracks the orientation of the transducer during the scan and sends this information to the Infinity Workstation via Bluetooth. The Infinity Workstation combines information from the Infinity Box and Sensor to generate tomographic 3D ultrasound volumes on which the abovedescribed image analysis can be performed.
The PIUR tUS Infinity acts as part of the diagnostic chain only and must not be used as a sole source for diagnostic or treatment decisions.
The solution is intended to be used on patients aged 22 and older, independent of gender, linguistic and cultural background, or health status, unless any of the contraindications apply, in a non-sterile environment. The solution is not intended to be used on patients with open wounds or irritated skin or during surgery.
Indications for Use
PIUR tUS Infinity is a computer-aided detection device intended to assist and support medical professionals in the diagnostic workflow of thyroid and thyroid nodules acquired from FDAcleared ultrasound systems, including image documentation, and reporting. The device supports the physician with additional information during image review, including quantification and visualization of sonographic characteristics of thyroid nodules.
PIUR tUS Infinity may be used on any adult patient aged 22 and older, independent of gender, linguistic and cultural background, or health status, unless any of the contraindications apply.
The PIUR tUS Infinity acts as part of the diagnostic chain and must not be used as a sole source for treatment decisions, but as an add-on solution to regular 2D ultrasound imaging.
PIUR tUS Infinity device is not intended for body contact (including skin, mucosal membrane, breached or compromised surfaces, blood path indirect, tissues, bones, dentin, or circulation blood).
Technological Characteristics
The PIUR tUS Infinity system provides the following functions:
- . Use of ultrasound image post-processing to aid in the diagnosis of thyroid diseases.
- . Operates in combination with hardware to generate 3D volumes. The Infinity Sensor is connected to the ultrasound transducer to detect probe movement for spatial 3D information. This use of hardware allows for reduced inter- and intra-observer variability compared to 2D ultrasound.
6
- Provides volumetric information as diagnostic output for the thyroid lobe and nodule as . additional information. This includes nodule volume, which can be important for evaluating nodule growth over time.
Performance Standards
PIUR tUS Infinity has been developed in conformance with the following standards and FDA guidance, as applicable:
- ISO 13485:2016, Quality management systems Requirements for regulatory purposes ●
- ISO 14971:2019, Medical devices Application of risk management to medical devices ●
- IEC 62366-1:2015, Medical devices Part 1: Application of usability engineering to ● medical devices
- IEC 62304:2015, Medical device software Software lifecycle processes ●
- IEC 82304-1:2016, Health Software Part 1: General Requirements for Product Safety ●
- EN 301 489-1 V2.2.3 (2019-11) Electromagnetic compatibility (EMC) standard for ● radio equipment and services; Part I: common technical requirements; Harmonized standard covering essential requirements of article 3.1b of Directive 2014/53/EU and the essential requirements of article 6 of Directive 2014/30/EU
- EN 301 489-17 V3.2.4:2020 Electromagnetic compatibility and Radio spectrum . Matters (ERM); Electromagnetic compatibility (EMC) standard for radio equipment; Part 17: Specific conditions for Broadband Data Transmission Systems
- IEC 60601-1:2013 Medical electrical equipment Part 1: General requirements for . basic safety and essential performance
- . IEC 60601-1-2:2014 – Medical electrical equipment General requirements for basic safety and essential performance. Collateral Standard: Electromagnetic disturbances. Requirements and tests
- IEC 60601-2-37:2016 Medical electrical equipment Part 2-37: Particular requirements . for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment
- . ISO 15223-1:2021, Medical devices — Symbols to be used with information to be supplied by the manufacturer — Part 1: General requirements
- IEC 60417:2002, Graphical symbols for use on equipment ●
- NEMA PS 3.1-3.20:2016, Digital Imaging and Communications in Medicine (DICOM) ●
- Content of Premarket Submissions for Management of Cybersecurity in Medical ● Devices, September 2023
- Computer-Assisted Detection Devices Applied to Radiology Images and Radiology . Device Data - Premarket Notification [510(k)] Submissions, September 2022
7
Performance Data
The PIUR tUS Infinity system complies with DICOM (Digital Imaging and Communications in Medicine), developed by the American College of Radiology and the National Electrical Manufacturers Association - NEMA PS 3.1-3.20.
PIUR Imaging conducted summative usability evaluation, performance validation testing and software verification and validation testing of the PIUR tUS Infinity system. The results of the usability and performance validation testing demonstrated that the PIUR tUS Infinity system provides accurate representation of key processing parameters under a range of clinically relevant parameters associated with the intended use of the software performance, validation and verification testing demonstrated that the PIUR IUS Infinity system met all design requirements and specifications.
To validate the safety and performance of the PIUR tUS Infinity System software and machine learning algorithms, PIUR conducted performance testing that consisted of two major parts:
-
- Volume Measurement Validation
- a. Demonstrate non-inferiority of volume measurements against conventional protocol using:
- i. Standardized (%) absolute inter-observer differences
- ii. Lin's Concordance Correlation Coefficient
- iii. Mean Squared Error
-
- ACR TI-RADS Classification Validation
- a. Demonstrate non-inferiority of the PIUR tUS Infinity in ACR TI-RADS classification against conventional 2D ultrasound using Weighted Cohen's Kappa coefficient in 196 male and female patients (US, Europe & Brazil) across multiple ethnicities and using 7 ultrasound models (covering low-end, mid-range, and high-end scanners).
- b. In addition, PIUR assessed performance for individual ACR TI-RADS subparameters to exclude bias or distortion introduced by 3D reconstruction using a sub-set of 102 patients. Weighted Cohen's Kappa Coefficients and Limits of Agreement for ultrasound categories (total score, composition, echogenicity, shape, margin and echogenic foci) were assessed on thyroid nodules.
Electrical safety and EMC testing were conducted on the PIUR Infinity. The testing complies with the applicable sections of IEC 60601-1:2013, Medical electrical equipment – Part 1: General requirements for basic safety and essential performance. IEC 60601-1-2:2014, Medical electrical equipment – Part 1-2: General requirements for the basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests, and IEC 60601-2-37:2016, Medical electrical equipment - Part 2-37: Particular requirements for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment. An additional white-noise test verified that the use of the wireless PIUR tUS Infinity equipment does not induce any additional white noise band in the ultrasound image, and
8
therefore, does not degrade the quality of ultrasound images
Together with software verification and validation, safety and performance testing demonstrated that PIUR tUS Infinity system satisfies all design requirements and device specifications and is substantially equivalent to the Predicate Device.
Substantial Equivalence
In comparison with the Predicate AmCAD device (K203555), the PIUR tUS Infinity device has the same intended use / indications, technological characteristics and principles of operation as described in the comparison table below.
| Description | Subject Device | Predicate Device (K203555) |
|---|---|---|
| Product Name | PIUR tUS Infinity | AmCAD-UT |
| Manufacturer | PIUR Imaging GmbH | AmCad BioMed Corporation |
| Product Code /Regulation | QIH / 21CFR 892.2050 | QIH / 21CFR 892.2050 |
| Indications forUse | PIUR tUS Infinity is a computer-aided | |
| detection device intended to assist and | ||
| support the medical professionals in the | ||
| diagnostic workflow of thyroid and | ||
| thyroid nodules acquired from FDA- | ||
| cleared ultrasound systems, including | ||
| image documentation, analysis, and | ||
| reporting. The device supports the | ||
| physician with additional information | ||
| during image review, including | ||
| quantification and visualization of | ||
| sonographic characteristics of thyroid | ||
| nodules. |
PIUR tUS Infinity may be used on any
adult patient aged 22 and older,
independent of gender, linguistic and
cultural background, or health status,
unless any of the contraindications
apply.
PIUR tUS Infinity device is not
intended for body contact (including
skin, mucosal membrane, breached or
compromised surfaces, blood path
indirect, tissues, bones, dentin, or
circulation blood). | AmCAD-UT is a Windows-based
computer-aided detection (CADe)
device intended to assist the medical
professionals in analyzing thyroid
ultrasound images, acquired from
FDA-cleared ultrasound systems.
The region of interest (ROI) of a
user-selected thyroid nodule is
defined by users or suggested by an
Al contouring algorithm. After the
initial review of the ultrasound
images by the physicians, the device
further provides detailed information
with quantification and visualization
of sonographic characteristics of
thyroid nodules. The device is
intended for use on ultrasound
images of discrete thyroid nodules
larger than Icm, for which a biopsy
recommendation is required. |
| Description | Subject Device | Predicate Device (K203555) |
| Functional
Capability of
Image Processing | The device performs 2D to 3D
reconstruction to generate volumetric
data of a thyroid. User-selected
computer vision and machine learning
algorithm suggested volumes of thyroid
lobe and nodules are visualized to be
confirmed by user. The system provides
a user interface for the user to manually
select sonographic characteristics of
each nodule (hyperechoic foci,
echogenicity, texture, margin,
orientation and anechoic areas) from
which an ACR TI-RADS score will be
computed. | AmCAD-UT analyzes the user-
defined or AI-suggested regions of
interest (ROI) of a user-selected
thyroid nodule for detection and
quantification of sonographic
characteristics (hyperechoic foci,
echogenicity, texture, margin,
orientation and anechoic areas). The
device further provides detailed
information with visualization of
sonographic characteristics of
thyroid nodules. |
| Reading
Paradigm | Device provides quantification and
visualization of sonographic
characteristics based on 3D volumetric
data. Results provide proposals to be
reviewed and confirmed by physicians. | AmCAD-UT is to provide
quantification and visualization of
sonographic characteristics after
physicians' initial review of the
images. |
| Output Generated
by the CAD
Device | The device can export volumetric data,
annotated screenshots and reports.
Report can contain both sides of the
patient and includes all relevant
diagnostic information. | The image can be annotated with the
detected sonographic characteristics
and be recorded by the device. The
software also automatically
generates reports given the user
preference inputs in the analysis
process. |
| Type of Film to be
Processed by the
CAD Device | Digital ultrasound videoclip (cineloop) | Digital ultrasound image |
| Software Design | Based on computer vision, machine
learning, pattern recognition and
quantification method. | Based on AI, Statistical Pattern
Recognition and Quantification
method |
| Ground Truth
Establishment | The ground truth to be established for
performance studies of the device are
annotated data sets labeled by medical
specialists. | The ground truth to be established
for performance studies of the device
is the ROI labeled by a panel of
specialists. |
| Platform | Windows-based | Same |
| Operating System | Standard PC or review station | Same |
| Clinical
Application | Thyroid Lesions | Thyroid cancers |
| Image Type | Ultrasound volume image | Ultrasound Image |
| Description | Subject Device | Predicate Device (K203555) |
| Image Format | DICOM format:
Secondary Capture Image Storage -
1.2.840.10008.5.1.4.1.1.7
Multi-frame Grayscale Byte Secondary
Capture Image Storage -
1.2.840.10008.5.1.4.1.1.7.2
Multi-frame True Color Secondary
Capture Image Storage -
1.2.840.10008.5.1.4.1.1.7.4
Refer to: DICOM-Conformance
Statement-PIUR tUS Infinity | DICOM3.0, Bitmap, JPEG |
| ROI
Quantification | Yes | Yes |
| Automatically
Generating
Report | Yes | Same |
| Performance
Testing Data to
Support SE
Determination | Results from standalone performance
testing of machine learning algorithm
suggested ROIs of user-selected
nodules | Results from standalone performance
testing of AI suggested ROI's of
user-selected nodules |
| Device
Components | Infinity Box
Infinity Sensor
Infinity Software | N/A - Predicate is a software only
device (SaMD) |
| DICOM
Compliance | Yes | Same |
| Data Acquisition | Acquires medical image data from
DICOM compliant Ultrasound imaging
devices | Same |
| Data / Image
Types | Ultrasound image via DICOM format | Same |
Table 4: Substantial Equivalence Comparison Table
9
10
Conclusions
The PIUR tUS Infinity system performs as intended and presents no unacceptable risks to the intended patient population. The performance testing supports the safety of the device and demonstrate that the PIUR tUS Infinity system performs as intended in the specified use conditions. The PIUR tUS Infinity system is substantially equivalent in intended use, technological characteristics, safety, and performance characteristics to the legally marketed Predicate AmCAD-UT Device (K203555).